Valneva Announces Sale of Priority Review Voucher for $103 Million
Valneva SE announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million).
The Company was awarded a…
Read More...
Read More...